Pre-made Ticilimumab benchmark antibody ( Whole mAb, anti-CTLA4/CTLA-4 therapeutic antibody, Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Ticilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Tremelimumab (formerly ticilimumab, CP-675,206) is a fully human monoclonal antibody against CTLA-4. It is an immune checkpoint blocker. Previously in development by Pfizer, it is now in investigation by MedImmune, a wholly owned subsidiary of AstraZeneca. It has been undergoing human trials for the treatment of various cancers but has not attained approval for any.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-569-1mg	1mg	3090
GMP-Bios-ab-569-10mg	10mg	Inquiry
GMP-Bios-ab-569-100mg	100mg	Inquiry
GMP-Bios-ab-569-xmg	＞100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Ticilimumab biosimilar, Whole mAb, Anti-CTLA4/CTLA-4 Antibody: Anti-CD/GSE/GRD4/ALPS5/CD152/IDDM12/CELIAC3 therapeutic antibody
INN Name	Ticilimumab
Target	CTLA-4
Format	Whole mAb
Derivation
Species Reactivity	Human
CH1 Isotype	IgG2
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Active
100% SI Structure	5ggu:HL:AB/5ggv:HL
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2005
Year Recommended	2008
Companies	AIO Studien gGmbH;Amgen;ARCAGY/GINECO Group;AstraZeneca;Azienda Ospedaliera Universitaria Senese;Canadian Cancer Trials Group;Charite - Universitatsmedizin Berlin;Dana-Farber Cancer Institute;Fondazione IRCCS Istituto Nazionale dei Tumori;Grupo Espanol de Tumores Neuroendocrinos;Hoosier Cancer Research Network;Immunocore;Institute Gustave-Roussy;Kyoto Breast Cancer Research Network;M. D. Anderson Cancer Center;MedImmune;Memorial Sloan-Kettering Cancer Center;National Cancer Institute (USA);Northwestern University;Pfizer;Seoul National University Hospital;UNICANCER;University College London;University of Maryland Greenbaum Cancer Center;Yonsei University College of Medicine
Conditions Approved	na
Conditions Active	Head and neck cancer;Liver cancer;Mesothelioma;Non-small cell lung cancer;Renal cell carcinoma;Small cell lung cancer;Solid tumours;Urogenital cancer;Biliary cancer;Bladder cancer;Breast cancer;Cholangiocarcinoma;Colorectal cancer;Endometrial cancer;Fallopian tube cancer;Gallbladder cancer;Gastric cancer;Gastrointestinal cancer;Germ cell and embryonal neoplasms;Glioblastoma;Lung cancer;Neuroendocrine tumours;Oropharyngeal cancer;Ovarian cancer;Pancreatic cancer;Peritoneal cancer;Prostate cancer;Sarcoma;Soft tissue sarcoma;Thyroid cancer;Haematological malignancies;Malignant melanoma;Oesophageal cancer;Cervical cancer
Conditions Discontinued	Diffuse large B-cell lymphoma;Gynaecological cancer;Myelodysplastic syndromes
Development Tech	Abgenix XenoMouse